An observational study in Stroke, Acute Ischemic Stroke and Acute Ischemic Stroke AIS, sponsored by Karolinska Institutet. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Karolinska Institutet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Ischemic Stroke with a site in Finland — 6 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Finland.
Among the 38 studies in Ischemic Stroke with a site in Finland, this one is the only one that started in 2026, is one of 8 observational ones, and was the 38th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →6 of the 38 studies in Ischemic Stroke with a site in Finland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Finland, Austria, Belgium and 9 more countries
Ages 18+
Finnish Institute of Occupational Health · Sites in Finland
Ages 18–68
University Hospital, Basel, Switzerland · Sites in Finland, United States, Argentina and 6 more countries
Ages 18+ · Women only
Jukka Putaala · Sites in Finland
Ages 40+
Medtronic Neurovascular Clinical Affairs · Sites in Finland, Argentina, Australia and 21 more countries
Ages 18+
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 495 across the 30 interventional studies, 1,200 across the 8 observational. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 38 have an industry lead sponsor. The 10 most frequent:
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Karolinska Institutet has 8 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
1 of the studies in Ischemic Stroke with a site in Finland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06709898Finnish Institute of Occupational HealthStroke in Working Age and Job Accommodation in Facilitating Transition Back to Work | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies in Ischemic Stroke with a site in Finland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn how the timing of mobilisation after endovascular thrombectomy (EVT) affects complications in patients with acute ischaemic stroke. The main questions it aims to answer are:
Does mobilisation approximately 12 hours after EVT, compared to approximately 24 hours after EVT, affect the risk of complications such as access site haematoma (ASH), venous thromboembolism (VTE), infections, and delirium? How common are these complications after EVT, and which factors are associated with increased risk?
Participants undergoing EVT as part of their regular stroke care at two hospitals with different mobilisation routines will be followed during their hospital stay. Researchers will collect information about mobilisation timing, complications, clinical assessments, and medical history using case report forms, electronic health records, and national stroke registries.
Title Mobilisation After Endovascular STROke treatment (MAESTRO): A prospective multicentre cohort study
Background and Rationale Stroke remains one of the leading causes of death and long-term disability worldwide. Each year, approximately 12-15 million people experience a stroke, with ischaemic stroke accounting for around two-thirds of cases. In Sweden alone, more than 26,000 individuals are affected annually, and the majority of patients are elderly. Beyond mortality, stroke often results in significant disability and dependency, requiring extensive rehabilitation and long-term care.
Over the past decade, endovascular thrombectomy (EVT) has revolutionised treatment for acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO). Randomised controlled trials have demonstrated substantial improvements in functional outcome for patients undergoing EVT compared to medical therapy alone, with benefits extending up to 24 hours after stroke onset. EVT has therefore become standard of care for selected patients with LVO.
While EVT has improved prognosis, it also introduces new challenges in the acute post-procedural phase. Most procedures are performed via femoral artery access, necessitating a period of strict bed rest to reduce the risk of access site haematoma (ASH). Patients often recover neurologically within hours, however, and may wish to mobilise earlier than current routines allow. The optimal timing of mobilisation after EVT remains unclear. Early mobilisation may reduce complications of immobility, but may also increase the risk of ASH. Conversely, prolonged bed rest may lower the risk of ASH but increases the risk of venous thromboembolism (VTE), infections such as pneumonia and urinary tract infection (UTI), and delirium. These complications are common after stroke, associated with worse outcomes, and prolong hospital stay.
Reported incidence of ASH varies widely, from 1% to 10%, likely due to inconsistent definitions and underreporting.
VTE after EVT has been reported in more than a quarter of patients in some studies, particularly among those with severe motor deficits or prolonged procedures. Post-stroke pneumonia affects more than one third of thrombectomy-treated patients and is independently associated with increased mortality and reduced independence. Delirium is a frequent complication among acute stroke patients, characterised by altered consciousness, disorganised thinking or disorientation, psychomotor disturbances, and circadian rhythm disruption, and is associated with worse outcomes. However, evidence regarding delirium after mechanical thrombectomy (MT) remains limited, as most previous studies were conducted in mixed stroke cohorts with few MT cases or predate the thrombectomy era. Together, these complications underscore the clinical importance of identifying safe and effective mobilisation strategies.
Despite the relevance of these issues, few studies have systematically investigated mobilisation after EVT. Available evidence is limited, definitions vary across studies, and results are contradictory. There is currently no consensus on when mobilisation should be initiated after EVT, leaving clinicians with considerable uncertainty. This knowledge gap has direct implications for patient safety, recovery, and the development of evidence-based care protocols.
Aim and Research Questions The overarching aim of this study is to investigate how the timing of mobilisation after EVT influences the occurrence of complications. The study will also describe the frequency, timing, and risk factors of complications related to mobilisation and immobilisation.
Research questions:
Participants and eligibility All adult patients (≥ 18 years) undergoing endovascular thrombectomy (EVT) for acute ischaemic stroke (AIS) at either participating centre will be consecutively screened for eligibility according to the inclusion and exclusion criteria listed below.
Inclusion criteria
In Sweden, presumed consent will be applied in rare cases where neither the patient nor a next of kin can provide consent, for example due to severe aphasia or unconsciousness. In such cases, inclusion will occur since participation poses no additional burden or risk, and only when every reasonable effort will have been made to obtain informed consent as soon as possible. No patient who expresses unwillingness or hesitation will ever be included.
Exposure and outcomes The primary exposure is the timing of first mobilisation after EVT, defined by local routine and recorded prospectively for each patient. Mobilisation includes sitting at the bedside with feet on the floor or in a chair/wheelchair, standing, or walking. Positioning in bed with elevated head of bed does not count as mobilization in this study. The primary outcome is ASH. Secondary outcomes include VTE (deep vein thrombosis or pulmonary embolism), infections (pneumonia or urinary tract infection), and delirium. The timing of these events in relation to EVT completion and mobilisation will be documented when available.
Data collection
Data collection is based on three complementary components:
The prospective CRF (see Appendix 1, CRF Prospective monitoring) includes:
Prospective data will be registered for as long as the patient remains admitted to the stroke unit, but for a maximum of five days, after which registration will stop.
Retrospective variables are obtained primarily from EHR, supplemented by national quality registries when not available in EHR (applicable for Sweden). These include demographics, comorbidities, medications, stroke severity, radiological findings, EVT-procedural details, blood pressure variability, infections (laboratory markers, antibiotic use, discharge diagnoses), VTE (discharge diagnoses or imaging reports), length of stay, discharge destination, functional status (Modified Rankin Scale [mRS] at 3 months), and mortality.
In Finland, due to national legislation requiring informed consent prior to data collection, early clinical data may in rare cases be retrieved retrospectively after inclusion and consent. This is possible as relevant parameters are already routinely documented within the local stroke care programme. It should be emphasised, however, that the study is primarily prospective, and any retrospective retrieval will only serve to capture early indicators of complications occurring before consent could be obtained.
Sample size and analysis A preliminary sample size calculation, assuming an ASH incidence of 10% in Finland and 20% in Sweden, indicated that approximately 400 patients (200 per site) are required to detect a statistically significant difference with α = 0.05 and power = 80%. This estimate is based on available literature and current clinical practice. Descriptive statistics will be used to summarise baseline characteristics and outcome frequencies. Categorical variables will be presented as counts and percentages, and continuous variables as means with standard deviations or medians with interquartile ranges.
Associations between mobilisation timing and complications will be analysed using multivariable logistic regression models, adjusting for potential confounders such as age, stroke severity, comorbidities, and procedural factors. Time-to-event analyses (Cox regression) may be applied where exact timing data are available. Subgroup analyses may be performed depending on data quality and sample size. Missing data will be handled using appropriate statistical methods depending on the extent and pattern of missingness.
Ethical considerations This study is observational and does not alter clinical care. Patients receive treatment according to the standard routines of each hospital. Prospective assessments, such as delirium screening, limb inspection, and ASH grading, are non-invasive, take only a few minutes, and entail no additional risk or discomfort for the patient. Data will be pseudonymised and stored in REDCap on secure EU servers, with access restricted to authorised research staff. All handling of personal data will comply with the General Data Protection Regulation (GDPR) and Karolinska Institutet's information security policies.
Significance This study addresses a critical knowledge gap in post-thrombectomy stroke care. By systematically comparing two mobilisation routines and documenting the frequency, timing, and risk factors of major complications, the study will generate evidence to guide safer and more individualised mobilisation protocols after EVT. The results may contribute to reducing complication rates, improving functional outcomes, and informing future clinical guidelines. Furthermore, the findings will provide a valuable basis for future scientific publications and for advancing the evidence base in stroke nursing and post-EVT care.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
This study's planned enrollment of 400 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients with acute ischaemic stroke treated with endovascular thrombectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Finnish cohort, mobilised after 24 hrs
Other: Mobilisation
Swedish cohort, mobilised after 12 hrs
Other: Mobilisation
Out of bed mobilisation, such as sitting on the edge of the bed, standing or walking with or without support.
Access site haematoma
Bleeding from puncture site
Time frame: From completion of endovascular thrombectomy (baseline) to discharge from the stroke unit, up to 5 days.
sICH
Symptomatic intracranial haemorrhage
Time frame: Within 36 hours after completion of endovascular thrombectomy
Venous thromboembolism
Blood clots in venous system, such as deep vein thrombosis and/or pulmonary embolism.
Time frame: From completion of endovascular thrombectomy until discharge from the acute care hospital, assessed up to approximately 30 days.
Infections
Urinary tract infections, pneumonia and/or sepsis.
Time frame: From completion of endovascular thrombectomy until discharge from the acute care hospital, assessed up to approximately 30 days.
Delirium
Acute confusion, identified with Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)
Time frame: From completion of endovascular thrombectomy (Baseline) to discharge from the stroke unit, up to 5 days.
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 19 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.